Abstract
PET/CT has proven to be highly accurate for staging of Hodgkin lymphoma. A recent study also reported that PET/CT detected additional disease sites in 50% of patients with peripheral T-cell lymphoma (PTCL) as compared to conventional CT-based staging and had higher sensitivity for extranodal disease. This may challenge the validity of pre-therapeutic prognostic tools such as the widely used international prognostic index (IPI), which contains imaging-depended clinical features such as Ann Arbor stage and extranodal disease.
To examine the validity of IPI in PET/CT staged PTCL patients treated with CHOP or CHOP-like first line therapies.
The present retrospective study included PTCL patients from five Danish referral hematology centers. Potential candidates for the study were identified from a search in the Danish Lymphoma Registry (LYFO). Patients with PTCL not otherwise specified (PTCL NOS), anaplastic large cell lymphoma (ALCL), or angioimmunoblastic T-cell lymphoma (AITL) were included if they underwent PET/CT staging and were treated with CHOP or CHOP-like first-line therapy +/- consolidating high-dose therapy. Medical records were retrieved and reviewed for all included patients.
During the time period 2006-2013 a total of 137 out of 259 PTCL patients were staged with PET/CT. Of these 119 (87%) received CHOP or CHOP-lile first-line therapy and were included in this analysis. The patients were diagnosed with PTCL NOS (n=49), AITL (n=18), and ALCL (n=52). The median age was 58 yrs. and the male:female ratio was 1.3. Advanced stage disease (III-IV) was diagnosed in 71% (n=85) and 27% (n=32) of the patients had more than one extranodal site involved. In univariate Cox regression analyses elevated LDH (HR 2.77, 95%CI 1.44-5.34), > 1 extranodal disease site (HR 3.09, 95%CI 1.67-5.72), age > 60 yrs. (HR 2.49, 95%CI 1.35-4.59), ECOG performance > 1 (HR 2.03, 95% CI 1.08-3.83), and Ann Arbor stage III-IV (HR 2.43 95%CI 1.08-5.73) were all significantly associated with inferior overall survival (OS). The presence of more than one extranodal disease site was an adverse prognostic factor for both age groups. In a multivariate Cox regression analysis including these variables, age > 60 yrs., > 1 extranodal site, and elevated LDH retained independent association with short OS. Using IPI score 0-1 (low-risk) as reference group score the HRs for death were 2.49 (95%CI 0.87-7.19) for low-intermediate, 4.31 (95%CI 1.53-12.09) for high-intermediate, and 12.74 (95%CI 4.43-36.61) for high risk patients. IPI-specific OS fractions are show in the figure.
Despite the potential stage migration associated with the introduction of new and more accurate imaging modalities such as PET/CT, the original IPI developed two decades ago continues to be a highly valid tool for predicting overall survival in PTCL patients treated with CHOP or CHOP-like first-line therapies.
TCEG, MBP, and LCG contributed equally to the present work.
No relevant conflicts of interest to declare.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal